Frequently asked questions References STEP 1 Trial: Semaglutide 2.4 mg for Weight Management (NEJM, 2021) GLP-1 Receptor Agonists: Mechanism and Clinical Use (PubMed) Semaglutide Prescribing Trends (JAMA Network Open, 2023) FDA Drug Shortage Database: Semaglutide Wegovy Prescribing Information (FDA) Endocrine Society Guidelines: Pharmacological Management of Obesity CDC: Healthy Weight Loss Safety Profile of GLP-1 RAs (PubMed, 2022) Glycogen and Water Weight (PubMed) Lean Mass Preservation During Weight Loss (PubMed) Medullary Thyroid Carcinoma Risk and GLP-1 RAs (PubMed)
Mistake 3: Not protecting from light
Importantly, the Summary of Product Characteristics for both Wegovy and Saxenda warn that acute kidney injury has been reported in association with dehydration from these gastrointestinal adverse events
"We're fighting the algorithm which is why more medical professionals need to be on social media, so we can start diluting the misinformation." Dr Byrom said peptide users worried about their health should see a doctor
A previous mediation analysis of semaglutide in adults with overweight or obesity suggested that less than one percentage point of the body weight reduction achieved with subcutaneous semaglutide was attributable to gastrointestinal adverse events (246)
DejgaardTF,FrandsenCS,HansenTSetal.Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol.2016;4(3):221 32
